BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has announced receiving positive feedback from the FDA on its pre-IND meeting for Bria-PROS+™, a new immunotherapy for prostate cancer, paving the way for a Phase 1/2 clinical study. The FDA has waived certain animal study requirements, expediting the development of Bria-PROS+™. BriaCell is also advancing its immunotherapy platform with other cancer treatments in development.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
